Source: Eur Respir J, 57 (1) 2003551; 10.1183/13993003.03551-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Anna J. Podolanczuk, Imre Noth, Ganesh Raghu. Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine. Eur Respir J, 57 (1) 2003551; 10.1183/13993003.03551-2020

Member's Comments

Luis Molinos Martin - 05.11.2021 09:06
Very interesting the reflections of this article

Related content which might interest you: Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Targeted treatment of idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2016; 47:1321-1323 Year: 2016 Idiopathic pulmonary fibrosis: approaches to diagnostic Source: Eur Respir J 2002; 20: Suppl. 38, 61s Year: 2002 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm Source: Eur Respir J 2015; 46: 512-520 Year: 2015 Idiopathic pulmonary fibrosis: time for greater expectations? Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018 Year: 2018 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2014; 43: 1237-1239 Year: 2014 Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches Source: Eur Respir J 2006; 28: 463-465 Year: 2006 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Idiopathic pulmonary fibrosis: tracking the true occurrence is challenging Source: Eur Respir J 2015; 46: 604-606 Year: 2015 LATE-BREAKING ABSTRACT: Inhibition of MAP3K19 - A novel therapeutic approach for treatment of IPF Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 A global registry for idiopathic pulmonary fibrosis: the time is now Source: Eur Respir J 2014; 44: 273-276 Year: 2014 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Approach to pathogenetic treatment of experimental pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 637s Year: 2006